EVO
NASD Evotec SE Sponsored ADR$1.35 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.35, $0.01 below the day’s high of $1.35
- YTD change
- -56.33%
- vs 20-day SMA
- -15.50%
- vs 200-day SMA
- -49.32%
Price ranges
Price & Performance
-1.78 (-56.89%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 94.7% away from all-time highs of $25.29
- EVO is down 56% since the beginning of the year
- EVO is down 66% over the past 12 months
- EVO is down 20% over the past 1 month
EVO reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -65.3%.
- Previous minute
- +$0.00
- Last hour
- -$0.01
- Last 5 days
- -18.98%
- vs 8-day SMA
- -14.70%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just–Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just–Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
